Weibin WU, Rui WANG, Ridong WU, et al. MiR-223 inhibits HMGB1 secretion from human arterial smooth muscle cells by down-regulating NLRP3[J]. Journal of Third Military Medical University, 2018, 40(15): 1399-1406.
DOI:
Weibin WU, Rui WANG, Ridong WU, et al. MiR-223 inhibits HMGB1 secretion from human arterial smooth muscle cells by down-regulating NLRP3[J]. Journal of Third Military Medical University, 2018, 40(15): 1399-1406. DOI: 10.16016/j.1000-5404.201801052.
MiR-223 inhibits HMGB1 secretion from human arterial smooth muscle cells by down-regulating NLRP3
摘要
目的
2
探讨microRNA-223(miR-223)下调人动脉平滑肌细胞(human arterial smooth muscle cells,HASMCs)高迁移率族蛋白B1(high mobility group box 1,HMGB1)分泌的作用机制。
To investigate the role and mechanism of microRNA-223 (miR-223) in down-regulation of high mobility group box 1 (HMGB1) secretion from human arterial smooth muscle cells (HASMCs).
Methods
2
HASMCs were isolated from the normal arteries of severe traumatic amputees or healthy donors without arteriosclerosis obliterans by tissue explants adherent and then identified by immunofluorescence assay of SM-α actin. Real-time quantitative PCR (RT-qPCR) and Western blotting were used to detect the activity of NLR family pyrin domain containing 3 (NLRP3) inflammasome in the HASMCs after treatment of lipopolysaccharides (LPS) and adenosine triphosphate (ATP). After transfection of miR-223 mimic
the expression of NLRP3 was detected through RT-qPCR and Western blotting. Dual-luciferase report system was performed to verify the regulatory relationships between miR-223 and NLRP3 after the 3'UTR mutation site of NLRP3 was designed. The level of HMGB1 in the supernatant of transfected HASMCs was measured by enzyme linked immunosorbent assay (ELISA).
Results
2
Treatment of LPS and ATP enhanced the activity of NLRP3 inflammasome (
P
<
0.05)
and improved the secretion of HMGB1 from the HASMCs (
P
<
0.05). Transfection of miR-223 mimic significantly down-regulated NLRP3 at both mRNA and protein levels (
P
<
0.05). Dual-luciferase report system indicated that NLRP3 was the direct target of miR-223 because of its mRNA 3'-UTR sequences being complementary to miR-223. HMGB1 secretion from HASMCs was remarkably decreased after transfection with miR-223 mimic (
P
<
0.01).
Conclusion
2
miR-223 can decreases expression of NLRP3 inflammasome at transcriptional level and then inhibit its activity
and subsequently suppress the secretion of HMGB1 from HASMCs.
关键词
Keywords
references
LIAPIS C D, AVGERINOS E D, KADOGLOU N P, et al . What a vascular surgeon should know and do about atherosclerotic risk factors[J ] . J Vasc Surg, 2009, 49(5):1348-1354. DOI:10.1016/j.jvs.2008.12.046.
HOSEINI Z, SEPAHVAND F, RASHIDI B, et al . NLRP3 inflammasome:Its regulation and involvement in atherosclerosis[J ] . J Cell Physi, 2018, 233(3):2116-2132. DOI:10.1002/jcp.25930.
WEN H, MIAO E A, TING J P. Mechanisms of NOD-like receptor-associated inflammasome activation[J]. Immunity, 2013, 39(3):432-441. DOI:10.1016/j.immuni.2013.08.037.
WILLINGHAM S B, ALLEN I C, BERGSTRALH D T, et al . NLRP3(NALP3, Cryopyrin) facilitates in vivo caspase-1 activation,necrosis, and HMGB1 release via inflammasome-dependent and-independent pathways[J ] . J Immunol, 2009, 183(3):2008-2015. DOI:10.4049/jimmunol.0900138.
BUI F Q, JOHNSON L, ROBERTS J, et al . Fusobacterium nucleatum infection of gingival epithelial cells leads to NLRP3 inflammasome-dependent secretion of IL-1beta and the danger signals ASC and HMGB1[J ] . Cell Microbiol, 2016, 18(7):970-981. DOI:10.1111/cmi.12560.
KANG R, CHEN R, ZHANG Q, et al . HMGB1 in health and disease[J ] . Mol Aspects Med, 2014, 40:1-116. DOI:10.1016/j.mam.2014.05.001.
VANDE W L, KANNEGANTI T D, LAMKANFI M. HMGB1 release by inflammasomes[J]. Virulence, 2011, 2(2):162-165.
BIANCHI M E, CRIPPA M P, MANFREDI A A, et al . High-mobility group box 1 protein orchestrates res ponses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair[J ] . Immunol Rev, 2017, 280(1):74-82. DOI:10.1111/imr.12601..
UGRINOVA I, PASHEVA E. HMGB1 protein:a therapeutic target inside and outside the cell[J]. Adv Protein Chem Struct Biol, 2017, 107:37-76. DOI:10.1016/bs.apcsb.2016.10.001.
CAI J, WEN J, BAUER E, et al . The role of HMGB1 in cardiovascular biology:danger signals[J ] . Antioxid Redox Signal, 2015, 23(17):1351-1369. DOI:10.1089/ars.2015.6408.
WANG K, LI W, YU Q, et al . High mobility group Box 1 mediates interferon-gamma-induced phenotypic modulation of vascular smooth muscle cells[J ] . J Cell Biochem, 2017, 118(3):518-529. DOI:10.1002/jcb.25682.
HUANG S C, WANG M, WU W B, et al . Mir-22-3p inhibits arterial smooth muscle cell proliferation and migration and neointimal hyperplasia by targeting HMGB1 in arteriosclerosis obliterans[J ] . Cell Physiol Biochem, 2017, 42(6):2492-2506. DOI:10.1159/000480212.
SCHWARTZ S M. Perspectives series:cell adhesion in vascular biology. Smooth muscle migration in atherosclerosis and restenosis[J]. J Clin Invest, 1997, 99(12):2814-2816. DOI:10.1172/JCI119472.
OWENS G K, KUMAR M S, WAMHOFF B R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease[J]. Physiol Rev, 2004, 84(3):767-801. DOI:10.1152/physrev.00041.2003.
FARH K K, GRIMSON A, JAN C, et al . The widespread impact of mammalian MicroRNAs on mRNA repression and evolution[J ] . Science, 2005, 310(5755):1817-1821. DOI:10.1126/science.1121158.
SHAN Z, QIN S, LI W, et al . An endocrine genetic signal between blood cells and vascular smooth muscle cells:role of microRNA-223 in smooth muscle function and atherogenesis[J ] . J Am Coll Cardiol, 2015, 65(23):2526-2537. DOI:10.1016/j.jacc.2015.03.570.
LU X, KAKKAR V. Inflammasome and atherogenesis[J]. Curr Pharm Des, 2014, 20(1):108-124.
ZHOU C, JI X Z, LIU Q, et al .Molecular mechanism of cholesterol sensor SCAP dysfunction in athero ma formation in ApoE-/-mice induced by inflammation[J ] .J Third Mil Med Univ, 2016, 38(9):938-943. DOI:10.16016/j.1000-5404.201510111.
GROH L, KEATING S T, JOOSTEN L, et al . Monocyte and macrophage immunometabolism in atherosclerosis[J ] . Semin Immunopathol, 2018, 40(2):203-214. DOI:10.1007/s00281-017-0656-7.
TALL A R, YVAN-CHARVET L. Cholesterol, inflammation and innate immunity[J]. Nat Rev Immunol, 2015, 15(2):104-116. DOI:10.1038/nri3793.
HANEKLAUS M, O'NDILL L A, COLL R C. Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation:recent developments[J]. Curr Opin Immunol, 2013, 25(1):40-45. DOI:10.1016/j.coi.2012.12.004.
GREBE A, LATZ E. Cholesterol crystals and inflammation[J]. Curr Rheumatol Rep, 2013, 15(3):313. DOI:10.1007/s11926-012-0313-z.
SAMSTAD E O, NIYONZIMA N, NYMO S, et al . Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release[J ] . J Immunol, 2014, 192(6):2837-2845. DOI:10.4049/jimmunol.1302484.
JIANG Y, WANG M, HUANG K, et al . Oxidized low-density lipoprotein induces secretion of interleukin-1beta by macrophages via reactive oxygen species-dependent NLRP3 inflammasome activation[J ] . Biochem Biophys Res Commun, 2012, 425(2):121-126. DOI:10.1016/j.bbrc.2012.07.011..
HOSEINI Z, SEPAHVAND F, RASHIDI B, et al . NLRP3 inflammasome:Its regulation and involvement in atherosclerosis[J ] . J Cell Physiol, 2018, 233(3):2116-2132. DOI:10.1002/jcp.25930.
BENNETT M R, SINHA S, OWENS G K. Vascular smooth muscle cells in atherosclerosis[J]. Circ Res, 2016, 118(4):692-702. DOI:10.1161/CIRCRESAHA.115.306361.
LACOLLEY P, REGNAULT V, SEGERS P, et al . Vascular smooth muscle cells and arterial stiffening:relevance in development, aging, and disease[J ] . Physiol Rev, 2017, 97(4):1555-1617. DOI:10.1152/physrev.00003.2017.
YIN Y W, LIAO S Q, ZHANG M J, et al . TLR4-mediated inflammation promotes foam cell formation of vascular smooth muscle cell by upregulating ACAT1 expression[J ] . Cell Death Dis, 2014, 5:e1574. DOI:10.1038/cddis.2014.535.
FISHER E A, MIANO J M. Don't judge books by their covers:vascular smooth muscle cells in arterial pathologies[J]. Circulation, 2014, 129(15):1545-1547. DOI:10.1161/CIRCULATIONAHA.114.009075.
VENGRENYUK Y, NISHI H, LONG X, et al . Cholesterol loading reprograms the microRNA-143/145-myocardin axis to convert aortic smooth muscle cells to a dysfunctional macrophage-like phenotype[J ] . Arterioscler Thromb Vasc Biol, 2015, 35(3):535-546. DOI:10.1161/ATVBAHA.114.304029.
SCAFFIDI P, MISTELI T, BIANCHI M E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation[J]. Nature, 2002, 418(6894):191-195. DOI:10.1038/nature00858.
PORTO A, PALUMBO R, PIERONI M, et al . Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein[J ] . FASEB J, 2006, 20(14):2565-2566. DOI:10.1096/fj.06-5867fje.
BAUERNFEIND F, RIEGER A, SCHILDBERG F A, et al . NLRP3 inflammasome activity is negatively controlled by miR-223[J ] . J Immunol, 2012, 189(8):4175-4181. DOI:10.4049/jimmunol.1201516.
NEUDECKER V, HANEKLAUS M, JENSEN O, et al . Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome[J ] . J Exp Med, 2017, 214(6):1737-1752. DOI:10.1084/jem.20160462..
Molecular mechanism of cholesterol sensor SCAP dysfunction in atheroma formation in ApoE-/- mice induced by inflammation
Lindley eupatorium herb extract prevents and attenuates vascular inflammation reaction in atherosclerosis rabbits
Loss-of-function MAVS mutation causes antiviral immunodeficiency: unveiling a novel mechanism linking viral infection to generalized pustular psoriasis in children
Z-Ligustilide ameliorates retinitis pigmentosa via inhibiting PI3K/AKT-inflammation axis: Validation based on network pharmacology and molecular docking
ATF3 regulates macrophage autophagy and inflammatory responses by suppressing ATG5 and ATG16L1 expression
Related Author
周超
季新忠
刘巧
伍莎莎
欧阳南
王柯静
程渝
周远大
Related Institution
Department of Pediatric Research Institute,Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders
Department of Dermatology, Children’s Hospital of Chongqing Medical University
Department of Ophthalmology, First Affiliated Hospital, Army Medical University (Third Military Medical University)
Department of Ophthalmology, General Hospital of Southern Theater Command
Chongqing Key Laboratory of Biochemistry and Molecular Pharmacology